Table 1 Demographic and clinical characteristics of study subjects
Active LN | Inactive LN | CKD | HC | P value# | |
|---|---|---|---|---|---|
N | 86 | 33 | 30 | 27 | — |
Age (years), median (IQR) | 34.9 (17.8) | 37.0 (12.0) | 62.0 (12.5) | 33.0 (13.5) | 0.454 |
Gender female, n (%) | 80 (93.0%) | 30 (90.9%) | 12 (40.0%) | 22 (81.5%) | 0.696 |
Disease assessment, median (IQR) | |||||
SLEDAI | 12 (8) | 4 (2) | NA | NA | <0.001 |
rSLEDAI | 4 (4) | 0 (0) | NA | NA | <0.001 |
SLICC RAS | 11 (6) | 0 (0) | NA | NA | <0.001 |
System involvement, n (%) | |||||
Constitutional | 15 (17.4%) | 11 (33.3%) | NA | NA | 0.267 |
Mucocutaneous | 33 (38.4%) | 14 (42.4%) | NA | NA | 0.955 |
Musculoskeletal | 19 (22.1%) | 9 (27.3%) | NA | NA | 0.679 |
Neuropsychiatric | 0 (0.0%) | 3 (9.1%) | NA | NA | 0.829 |
Cardiorespiratory | 11 (12.8%) | 3 (9.1%) | NA | NA | 0.460 |
Gastrointestinal | 1 (1.2%) | 4 (12.1%) | NA | NA | 0.765 |
Renal | 86 (100.0%) | 33 (100.0%) | NA | NA | — |
Hematological | 33 (38.4%) | 6 (18.2%) | NA | NA | 0.175 |
Laboratory tests, median (IQR) | |||||
ESR (mm/h) | 40 (38.8) | 16 (17.0) | NA | NA | <0.001 |
C3 (g/L) | 0.6 (0.3) | 0.9 (0.3) | NA | NA | <0.001 |
C4 (g/L) | 0.1 (0.1) | 0.2 (0.1) | NA | NA | 0.003 |
eGFR (ml/min/m2) | 97.3 (66.2) | 117 (51.3) | 66.3 (50.6) | NA | 0.012 |
24-h urine protein (g/24h) | 3.1 (4.0) | 0.1 (0.1) | 3.0 (4.9) | NA | <0.001 |
ANA positive/tested | 75/75 | 10/10 | NA | NA | — |
Anti-U1RNP positive/tested | 31/75 | 3/7 | NA | NA | 0.94 |
Anti-dsDNA (IU/mL) | 26.1 (26.1) | 21.2 (27.6) | NA | NA | 0.93 |
Renal disease information, n (%) | |||||
LN group | |||||
LN II | 1 (1.2%) | NA | NA | NA | — |
LN III | 4 (4.7%) | NA | NA | NA | — |
LN III+V | 11 (12.8%) | NA | NA | NA | — |
LN IV | 24 (27.9%) | NA | NA | NA | — |
LN IV+V | 21 (24.4%) | NA | NA | NA | — |
LN V | 23 (26.7%) | NA | NA | NA | — |
Unclassified | 2 (2.3%) | NA | NA | NA | — |
AI, median (IQR) | 5 (7) | NA | NA | NA | — |
CI, median (IQR) | 3 (2) | NA | NA | NA | — |
CKD group | |||||
DN | NA | NA | 12 (40.0%) | NA | — |
MN | NA | NA | 5 (16.7%) | NA | — |
IgAN | NA | NA | 5 (16.7%) | NA | — |
FSGS | NA | NA | 2 (6.7%) | NA | — |
Others | NA | NA | 6 (20.0%) | NA | — |
Comorbidity, n (%) | |||||
Hypertension | 16 (18.6%) | 3 (9.1%) | NA | NA | 0.147 |
Diabetes | 1 (1.1%) | 0 (0.0%) | NA | NA | 0.787 |
Hyperlipidemia | 3 (3.5%) | 0 (0.0%) | NA | NA | 0.638 |
Osteonecrosis of femoral head | 8 (9.3%) | 1 (3.0%) | NA | NA | 0.410 |
Concurrent infection | 7 (8.1%) | 4 (12.1%) | NA | NA | 0.111 |
Urine G3BP/Cr (μg/mg), median (IQR) | 35.5 (41.5) | 14.7 (18.5) | 15.1 (31.4) | 7.66 (6.0) | 0.003 |
Urine G3BP (ng/ml), median (IQR) | 228 (267) | 123 (288) | 105 (222) | 152 (91.9) | <0.001 |
Urine Creatinine (mg/dl), median (IQR) | 71.2 (53.4) | 105 (87.3) | 74 (63.4) | 162 (97.9) | <0.001 |